Literature DB >> 11120445

Plasma appearance and distribution of astaxanthin E/Z and R/S isomers in plasma lipoproteins of men after single dose administration of astaxanthin.

M Østerlie1, B Bjerkeng, S Liaaen-Jensen.   

Abstract

Appearance, pharmacokinetics, and distribution of astaxanthin E/Z and R/S isomers in plasma and lipoprotein fractions were studied in 3 middle-aged male volunteers (37-43 years) after ingestion of a single meal containing a 100 mg dose of astaxanthin. The astaxanthin source consisted of 74% all-E-, 9% 9Z-, 17% 13Z-astaxanthin (3R,3'R-, 3R,3'S; meso-, and 3S,3'S-astaxanthin in a 1:2:1 ratio). The plasma astaxanthin concentration--time curves were measured during 72 hr. Maximum levels of astaxanthin (1.3 +/- 0.1 mg/L) were reached 6.7 +/- 1.2 hr after administration, and the plasma astaxanthin elimination half-life was 21 +/- 11 hr. 13Z-Astaxanthin accumulated selectively, whereas the 3 and 3'R/S astaxanthin distribution was similar to that of the experimental meal. Astaxanthin was present mainly in very low-density lipoproteins containing chylomicrons (VLDL/CM; 36-64% of total astaxanthin), whereas low-density lipoprotein (LDL) and high-density lipoprotein (HDL) contained 29% and 24% of total astaxanthin, respectively. The astaxanthin isomer distribution in plasma, VLDL/CM, LDL, and HDL was not affected by time. The results indicate that a selective process increases the relative proportion of astaxanthin Z-isomers compared to the all-E-astaxanthin during blood uptake and that astaxanthin E/Z isomers have similar pharmacokinetics.

Entities:  

Year:  2000        PMID: 11120445     DOI: 10.1016/s0955-2863(00)00104-2

Source DB:  PubMed          Journal:  J Nutr Biochem        ISSN: 0955-2863            Impact factor:   6.048


  35 in total

1.  Astaxanthin increases choroidal blood flow velocity.

Authors:  Michiyuki Saito; Kazuhiko Yoshida; Wataru Saito; Akio Fujiya; Kazuhiro Ohgami; Nobuyoshi Kitaichi; Hiroki Tsukahara; Susumu Ishida; Shigeaki Ohno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-10       Impact factor: 3.117

2.  Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans.

Authors:  Jean Soon Park; Jong Hee Chyun; Yoo Kyung Kim; Larry L Line; Boon P Chew
Journal:  Nutr Metab (Lond)       Date:  2010-03-05       Impact factor: 4.169

3.  Acute and chronic administration of disodium disuccinate astaxanthin (Cardax) produces marked cardioprotection in dog hearts.

Authors:  Garrett J Gross; Samuel F Lockwood
Journal:  Mol Cell Biochem       Date:  2005-04       Impact factor: 3.396

Review 4.  Neuroprotective mechanisms of astaxanthin: a potential therapeutic role in preserving cognitive function in age and neurodegeneration.

Authors:  Bethany Grimmig; Seol-Hee Kim; Kevin Nash; Paula C Bickford; R Douglas Shytle
Journal:  Geroscience       Date:  2017-02-13       Impact factor: 7.713

5.  Astaxanthin attenuates the increase in mitochondrial respiration during the activation of hepatic stellate cells.

Authors:  Minkyung Bae; Yoojin Lee; Young-Ki Park; Dong-Guk Shin; Pujan Joshi; Seung-Hyun Hong; Nathan Alder; Sung I Koo; Ji-Young Lee
Journal:  J Nutr Biochem       Date:  2019-06-20       Impact factor: 6.048

6.  Seven day oral supplementation with Cardax (disodium disuccinate astaxanthin) provides significant cardioprotection and reduces oxidative stress in rats.

Authors:  Garrett J Gross; Stanley L Hazen; Samuel F Lockwood
Journal:  Mol Cell Biochem       Date:  2006-02       Impact factor: 3.396

Review 7.  The Putative Role of Astaxanthin in Neuroinflammation Modulation: Mechanisms and Therapeutic Potential.

Authors:  Shuai Wang; Xin Qi
Journal:  Front Pharmacol       Date:  2022-06-24       Impact factor: 5.988

8.  Astaxanthin uptake in domestic dogs and cats.

Authors:  Jean Soon Park; Hong Wook Kim; Bridget D Mathison; Michael G Hayek; Stefan Massimino; Gregory A Reinhart; Boon P Chew
Journal:  Nutr Metab (Lond)       Date:  2010-06-21       Impact factor: 4.169

Review 9.  Astaxanthin: a potential therapeutic agent in cardiovascular disease.

Authors:  Robert G Fassett; Jeff S Coombes
Journal:  Mar Drugs       Date:  2011-03-21       Impact factor: 5.118

10.  Adonis amurensis Is a Promising Alternative to Haematococcus as a Resource for Natural Esterified (3S,3'S)-Astaxanthin Production.

Authors:  Yongfu Li; Fengying Gong; Shuju Guo; Wenjie Yu; Jianguo Liu
Journal:  Plants (Basel)       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.